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significantly improve chylomicron metabolism by independently decreasing the secretion of apoB-48.
INTRODUCTION

50
Elevated plasma triglyceride concentrations are directly related to risk of cardiovascular disease (CVD) 51 (1) . Hypertriglyceridemia is the most consistent lipid disorder in obesity and may contribute to increased 52 risk of CVD in these subjects (2) . Humans consume multiple meals during the day and, hence, are 53 continually in a dynamic state of postprandial lipid and lipoprotein metabolism (3) . 
65
Fish oils are a rich source of long-chain ω-3 fatty acids, primarily eicosapentaenoic acid (EPA) and 66 docosahexaenoic acid (DHA). Compelling evidence suggests that fish oil supplementation protects 67 against CVD and is partly mediated by improvement in hypertriglyceridemia (7) . However, two recent 68 clinical outcome trials with fish oil supplementation failed to show a significant CVD benefit in high risk 69 subjects including diabetics, possibly owing to a low dose of fish oil supplementation (~1g/day) being 70 employed (8, 9) . Data from a meta-analysis of 20 randomised trials also suggest that fish oil 71 supplementation was not associated with a lower risk of major CVD events (10) . However, most of 72 these studies were conducted using low dose fish oil supplementation (<2g/days). We have previously reported that a 6-week of high dose ω-3 fatty acid ethyl ester (ω-3 FAEE) supplementation resulted in 74 reductions in VLDL-apoB-100 and VLDL-triglyceride concentrations (11) . This could be related to 75 reductions in VLDL-apoB-100 and VLDL-triglyceride secretion rates in the postabsorptive state. Recent 76 evidence also suggests that ω-3 FAEEs could regulate chylomicron metabolism via an effect on apoB-48 77 synthesis (12) (13) (14) . However, fasting apoB-48 concentration was not altered with ω-3 FAEE 78 supplementation (Chan et al unpublished observation), probably owing to persistent insulin resistance in 79 obese subjects. Weight loss through dietary restriction is the first-line approach to correct dyslipidemia 80 and insulin resistance in obesity (15) . We previously demonstrated that intensive weight loss (>10%) 81 with a low caloric diet effectively lowers plasma concentrations of triglyceride-rich lipoproteins (TRLs), 82 including VLDL-apoB-100 and apoB-48, and also improves insulin sensitivity (16) . Hence, inclusion of 83 a weight loss component may enhance the effect of ω-3 FAEE supplementation on apoB-48 metabolism 84 in insulin resistant, obese subjects. However, such intensive weight loss is difficult to achieve and 85 maintain. Therefore, in a clinical setting, the combination of ω-3 FAEE supplementation and moderate 86 weight loss (3-5%) could be an optimal approach to improve postprandial hypertriglyceridemia, 87 especially chylomicron metabolism. To date, no kinetic study has examined the effect of ω-3 FAEE 88 supplementation on chylomicron metabolism in obese subjects on a moderate weight loss diet.
90
In the present study, we employed a new compartmental modelling to investigate the combined effects of 91 ω-3 FAEE supplementation and moderate weight loss on apoB-48 kinetics in a postprandial, non-steady 92 state setting (6) . We hypothesized that ω-3 FAEE would decrease fasting and postprandial apoB-48 93 concentrations chiefly by reducing apoB-48 secretion in obese subjects who were on a moderate weight 94 loss diet. 95 96 97 index >30kg/m 2 or waist circumference >94 cm for men and >80cm for women), who were 101 consuming ad libitum, weight maintaining diets were recruited from the community. None of 102 the subjects had familial hypercholesterolemia, APOE2/E2 genotype, macroproteinuria, raised 103 creatinine (>120µmol/L) with low glomerular filtration rate (<60 mL/min), hypothyroidism, 104 intolerance to fish oil or elevated hepatic aminotransferase or a history of CVD. Two subjects 105 dropped out due to time commitment. This study was approved by the Ethics Committee of the 106 Royal Perth Hospital, and informed consent was obtained in all subjects. 107
108
Clinical Protocol 109
This study was a randomised, single-blind intervention trial. All eligible patients entered a 4-110 week run-in diet stabilising period, at the end of which they entered a hypocaloric diet for 12 111 weeks immediately followed by a 4-week weight maintenance period. During the 16-week 112 intervention period, subjects were randomised into one of the two groups, weight loss alone 113 group or weight loss plus 4g/day Omacor (ω-3 FAEEs). Compliance with n-3 FAEE 114 supplementation was checked by capsule count at weeks 6, 12 and 16 post randomisation. For 115 the 12 weeks of weight loss, subjects were advised to reduce portions sizes in order to achieve 116 energy deficit of at least ~1900kJ. At the 4 weeks of weight maintenance period, energy intake 117 increased by ~460kJ. Dietary intake was assessed for energy and major nutrients using 118 FoodWorks 7 Pro (Xyris, Queenslandd Australia). Dietary intake, alcohol and exercise diaries 119 were completed at week 0, 6, 12 and 16. All subjects were reviewed fortnightly and requested to 120 maintain their usual level of physical activity. All dietary assessments and recommendations
Postprandial and stable isotope protocol 124
All subjects were admitted to the metabolic ward in the morning after a 14-hour fast. They were 125 studied in a semi-recumbent position and allowed to drink only water after the test-meal. Arterial 126 blood pressure was recorded after 3 minutes in the supine position using a Dinamap1846 SX/P 127 monitor (Critikon Inc, Tampa, FL, USA). Body composition was estimated using a Wedderburn (17) , and that the increase in plasma apoB-48 concentration was due to an increase in apoB-48 secretion 
Statistical Analyses 184
All analyses were performed on SPSS 21 (SPSS, Inc., Chicago). Paired t-tests were used to 185 assess changes within both treatment groups for all variables. Changes within group were 186 compared between the two intervention groups by ANCOVA using baseline as covariate. 187
Associations were examined using simple linear regression method. Statistical significance was 188 defined at the 5% level. 
226
The postprandial responses for plasma triglycerides and apoB-48 to the fat load are shown in Figure 1 .
227
As seen in Table 2 
285
Elevated fasting levels and postprandial responses of apoB-48 have been shown in obese subjects (6, 22) .
286
Disturbances in chylomicron metabolism in obesity may be due to an effect of insulin resistance and the 287 accumulation of visceral fat (23) (24) (25) (26) . Collectively, these conditions result in the oversecretion of TRLs, 288 suppressed LDL receptor activity and increased competition with VLDL remnants. Weight loss improves 289 insulin sensitivity and reduces visceral fat accumulation. We have previously reported that weight loss 290 lowered fasting VLDL-apoB-100 concentration by reducing its secretion rate (27) . Given apoB-48 and 291 VLDL apoB-100 are competing for the same catabolic pathway, it is likely that the reduction in VLDL-292 apoB-100 concentration with weight loss alone or ω-3 FAEE plus weight loss might directly impact on 293 apoB-48 catabolism. Such changes could collectively correct the abnormalities in apoB-48 metabolism by 294 enhancing the uptake of chylomicron remnants by liver. Consistent with this, we found that the FCRs of 295 apoB-48 increased with weight loss alone and weight loss plus ω-3 FAEE and that the percentage change 296 in apoB-48 FCR was inversely associated with change in VLDL-apoB-100 concentration.
Given that 297 none of these changes differed between these two groups, it is conceivable that all these favourable 298 changes were chiefly driven by the effects of weight loss. Our present results also found that mild-to-299 moderate weight loss alone had no significant effect on postprandial total apoB-48 AUC or apoB-48 300 secretion rate following a fat load. The findings might be different with a greater degree weight loss (16) .
triglyceride concentration and postprandial AUC responses of triglyceride compared with weight loss 303 alone. This improvement is likely to be a consequence of reductions in triglyceride-rich VLDL-apoB-100 304 and chylomicron apoB-48 particles with ω-3 FAEEs. We have previously reported that ω-3 FAEE 305 supplementation decreased the secretion of VLDL-apoB-100 and triglycerides in obese subjects (11, 28) .
306
Consistent with this, in the present study we showed that fasting VLDL-apoB-100 concentrations fell 
319
The precise reasons for the lack of an acute effect on apoB-48 metabolism remain unclear.
321
In this study, we employed a compartmental model to describe the non-steady kinetics of apoB-48 based 322 on a related study (6) , similar to the kinetic studies by Le et al (17) . The novelty of our approach has been 323 previously described (6) . Briefly, previous apoB-48 kinetic studies were conducted in a constant, fed 324 state which does not reflect usual daytime eating patterns (29, 30 Table 1 . Clinical, biochemical and haemodynamic characteristics in relation to weight loss alone and to weight loss plus ω-3 FAEE supplementation Table 2 . Postprandial changes for plasma triglyceride and apoB-48 following the oral fat load in relative to weight loss alone and weight loss plus ω-3 FAEE supplementation 
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